However, given the muscle involvement of systemic vasculitis [12], we suggest that even when patients can be classified as having PM/DM, the 2022 ACR/EULAR criteria for MPA should be applied simultaneously to patients with MPO-ANCA (or P-ANCA) and ILD. The gene discussed is MPO; the disease is dermatomyositis.